Contrary to common advice, the founder deliberately raised capital in small increments, never securing more than 12 months of runway. He found this self-imposed pressure was a powerful forcing function that kept him and the team sharp and focused on hitting critical milestones.

The CEO believes the most profound lessons in biotech come from speaking with founders of companies that did not succeed. In an industry defined by high clinical trial risk, understanding the missteps and navigating the challenges of unsuccessful ventures provides more practical wisdom than studying success stories alone.

While a challenging fundraising market seems negative, it forces startups to operate with discipline. Unlike in frothy markets where companies expand based on hype, the current climate rewards tangible results. This compels a lean structure focused on high-value projects, creating a healthier long-term business model.

Training in a resource-constrained Irish lab taught deep, focused thinking and prioritization—essential for running a lean startup. Conversely, a well-funded Boston lab enabled large-scale, exploratory science leading to breakthroughs. Hegarty credits this dual experience for his success in both academic discovery and biotech leadership.

Instead of hoarding early capital, Actuate's CEO synthesized a kilogram of their molecule and sent it to labs worldwide. The goal was to fail fast by seeing if promising results could be replicated, a crucial de-risking step before committing larger funds.

The transition from a resource-rich environment like Novartis to an early-stage biotech reveals a stark contrast. The unlimited access to a global organization is replaced by a total reliance on a small, nimble team where everyone must be multi-skilled and hands-on, a change even experienced executives find jarring.

For small biotechs, the playbook for success extends beyond scientific discovery. It requires creativity and innovation in the operational process itself—finding efficient paths through regulatory checkpoints, securing non-traditional funding, and leveraging external resources to advance development with limited capital.

Iolyx Therapeutics' CEO notes the surprising capital efficiency of lean biotech. Her team advanced a drug from discovery through Phase 2 for approximately $20 million—an amount she could have easily spent on a single marketing campaign at Genentech. This highlights the operational leverage of focused, small teams.

Luson Bioventures' Founder Derek Small learned his tech investment banking background was useless in biotech. The investors, 15-year timelines to revenue, and financial models were entirely different, forcing him to learn a new fundraising playbook from scratch.